Dublin-based pharmaceutical group Shire PLC on Tuesday said it had bid US$30 billion for Baxalta Inc to form a global biotech company, an offer soundly rejected by the US firm.
The industry is going through a period of consolidation and last week Israeli pharmaceutical giant Teva Pharmaceutical Industries Ltd said it was buying the generic drug business of Allergan PLC for US$40.5 billion.
“We believe the proposed combination of Shire and Baxalta would be strategically and financially attractive for both of our companies, accelerating our respective growth ambitions and creating the leading global biotech company in rare diseases,” Shire chief executive Flemming Ornskov said in a statement.
Shire said it made the unsolicited offer to Baxalta on July 10 at US$45.23 per Baxalta share, up 36 percent over Baxalta’s price on Monday.
Shire said a tie-up would generate US$20 billion in product sales by 2020. Shire and Baxalta each had revenues of about US$6 billion last year.
Ornskov said it was Shire’s “strong preference to immediately enter into a negotiated transaction to explore the full potential of the proposed combination and finalize the terms of an agreement.”
REJECTION
However, Baxalta on Tuesday said that it had rejected the Shire bid because it “significantly undervalues” Baxalta and its potential.
“Our board strongly believes that Baxalta’s independent global infrastructure and world-class manufacturing operations will provide an excellent platform to grow value for our shareholders,” Baxalta chief executive Ludwig Hantson said in a letter to Ornskov. “We are just in the initial stages of implementing our growth strategy as a standalone company and our stock has not yet achieved a price level that appropriately reflects the company’s value and prospects. A transaction at the exchange ratio you proposed significantly understates Baxalta’s true value.”
Meanwhile, EU regulators on Tuesday approved Pfizer Inc’s US$15.23 billion purchase of injectable drug and infusion device maker Hospira Inc.
DRUG SALES
The European Commission said Pfizer agreed to sell the European rights to experimental biosimilar version of the immune disorder drug Remicade and a few other products, including some chemotherapy drugs, in certain markets.
Pfizer, the second-largest drug company in the world in terms of revenue, agreed to buy Hospira of Lake Forest, Illinois, in February.
The purchase would strengthen the New York company’s position in the growing market for biosimilars, which are cheaper versions of biologic drugs. Pfizer has said it expects to complete the acquisition before the end of this year.
Additional reporting by AP
DECOUPLING? In a sign of deeper US-China technology decoupling, Apple has held initial talks about using Baidu’s generative AI technology in its iPhones, the Wall Street Journal said China has introduced guidelines to phase out US microprocessors from Intel Corp and Advanced Micro Devices Inc (AMD) from government PCs and servers, the Financial Times reported yesterday. The procurement guidance also seeks to sideline Microsoft Corp’s Windows operating system and foreign-made database software in favor of domestic options, the report said. Chinese officials have begun following the guidelines, which were unveiled in December last year, the report said. They order government agencies above the township level to include criteria requiring “safe and reliable” processors and operating systems when making purchases, the newspaper said. The US has been aiming to boost domestic semiconductor
Nvidia Corp earned its US$2.2 trillion market cap by producing artificial intelligence (AI) chips that have become the lifeblood powering the new era of generative AI developers from start-ups to Microsoft Corp, OpenAI and Google parent Alphabet Inc. Almost as important to its hardware is the company’s nearly 20 years’ worth of computer code, which helps make competition with the company nearly impossible. More than 4 million global developers rely on Nvidia’s CUDA software platform to build AI and other apps. Now a coalition of tech companies that includes Qualcomm Inc, Google and Intel Corp plans to loosen Nvidia’s chokehold by going
ENERGY IMPACT: The electricity rate hike is expected to add about NT$4 billion to TSMC’s electricity bill a year and cut its annual earnings per share by about NT$0.154 Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has left its long-term gross margin target unchanged despite the government deciding on Friday to raise electricity rates. One of the heaviest power consuming manufacturers in Taiwan, TSMC said it always respects the government’s energy policy and would continue to operate its fabs by making efforts in energy conservation. The chipmaker said it has left a long-term goal of more than 53 percent in gross margin unchanged. The Ministry of Economic Affairs concluded a power rate evaluation meeting on Friday, announcing electricity tariffs would go up by 11 percent on average to about NT$3.4518 per kilowatt-hour (kWh)
OPENING ADDRESS: The CEO is to give a speech on the future of high-performance computing and artificial intelligence at the trade show’s opening on June 3, TAITRA said Advanced Micro Devices Inc (AMD) chairperson and chief executive officer Lisa Su (蘇姿丰) is to deliver the opening keynote speech at Computex Taipei this year, the event’s organizer said in a statement yesterday. Su is to give a speech on the future of high-performance computing (HPC) in the artificial intelligence (AI) era to open Computex, one of the world’s largest computer and technology trade events, at 9:30am on June 3, the Taiwan External Trade Development Council (TAITRA) said. Su is to explore how AMD and the company’s strategic technology partners are pushing the limits of AI and HPC, from data centers to